Coya Therapeutics Common Net Asset
| COYA Stock | 4.32 -0.02 -0.46% |
| = | 49.95 M |
Coya Therapeutics' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets are sold, the net asset will be the amount that the shareholders would demand back from the fund.
Net Asset | = | Current Market Value | - | Current Liabilities |
Current Coya Therapeutics Net Asset | 49.95 M |
The Net Asset for Coya Therapeutics plays a role in the broader analysis that compares price to intrinsic value estimate. When core analysis points to a higher value than the market sets, it may signal a chance for more research. Trading below the model-implied intrinsic value estimate does not ensure a price rise - it indicates core data supports a higher estimate.
Net Asset Driver Correlations
The correlation matrix maps how Net Asset co-moves with Coya Therapeutics' other financial accounts across reporting periods. Positive correlations suggest shared drivers; negative correlations may reflect natural offsets within Coya Therapeutics' financial structure.
Click cells to compare fundamentals
| Competition |
Coya Total Assets
Total Assets | 28.87 Million |
Fundamental Drivers Relationships
Net Asset Peer Comparison
Peer comparison on Net Asset is one of the most widely used methods for evaluating Coya Therapeutics relative to competitors. Comparing Coya Therapeutics' Net Asset against peers surfaces securities trading below their model-implied intrinsic value estimate in the group.Coya Therapeutics is currently under evaluation in net asset among leading competitors.
Important Fundamentals
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | -2.67 | ||||
| Operating Margin | -1.08 | ||||
| Current Valuation | 56.62 M | ||||
| Shares Outstanding | 23.46 M | ||||
| Shares Owned By Insiders | 14.77 % | ||||
| Shares Owned By Institutions | 35.86 % | ||||
| Number Of Shares Shorted | 882.76 K | ||||
| Price To Book | 2.41 X | ||||
| Price To Sales | 12.81 X | ||||
| Revenue | 7.95 M | ||||
| Gross Profit | -8.79 M | ||||
| EBITDA | -20.24 M | ||||
| Net Income | -21.23 M | ||||
| Total Debt | 6.92 M | ||||
| Book Value Per Share | 2.06 X | ||||
| Cash Flow From Operations | -10.74 M | ||||
| Short Ratio | 6.38 X | ||||
| Earnings Per Share | -1.27 X | ||||
| Target Price | 15.64 | ||||
| Trailing Beta | 0.52 | ||||
| Market Capitalization | 101.8 M | ||||
| Total Asset | 49.95 M | ||||
| Retained Earnings | -61.96 M | ||||
| Working Capital | 44.07 M | ||||
| Net Asset | 49.95 M |
Financial Metrics, Fundamentals & Methodology
Coya Therapeutics's operating framework helps explain margin behavior, earnings persistence, and funding capacity. The company is currently operating at a loss. Overall market capitalization tier is micro-cap. For the latest reporting period, Coya Therapeutics reports revenue of 7.95 M, EPS loss of 1.27, negative operating margin of 107.51%.
Coya Therapeutics Common metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Analyst projections are included when active coverage applies. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board